Priothera is focused on developing innovative therapies to improve the treatment of hematological malignancies, particularly through the use of their investigational drug, mocravimod. This drug is designed to enhance the graft-versus-leukemia (GvL) effect while minimizing the risks associated with graft-versus-host disease (GvHD) in patients undergoing allogeneic Hematopoietic Cell Transplantation (HCT) and CAR-T cell therapy. Mocravimod is characterized as a first-in-class S1P receptor modulator, which has shown promise in clinical studies, including extensive Phase 1 and Phase 2a trials, and is currently in a registration-enabling Phase 3 study.

The company aims to address significant challenges in current treatment protocols for acute myeloid leukemia (AML) and other hematological cancers. By leveraging mocravimod's well-defined mechanism of action, Priothera seeks to improve survival rates and long-term outcomes for patients. Their commitment to research is further demonstrated by plans to explore mocravimod's application in CAR-T cell therapy, indicating a strategic approach to integrating their drug into existing treatment frameworks for enhanced efficacy.

France

Priothera - We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Priothera

Company Details